Abstract
Novel phenomena, such as constitutive activity and inverse agonism, have led to a ligand (re)classification along an agonists-neutral antagonist-inverse agonist continuum. This review focuses on adenosine A1 receptor ligands and their intrinsic activity (α). The intrinsic activity of a ligand depends both on the chemical characteristics of the compound itself and on the experimental conditions in which it is assayed. Consequently, due to this tissue-dependency determination of a ligands intrinsic activity is not always easily performed. Meanwhile, this feature may also be used in a profitable manner, namely to separate desired and unwanted effects of the drug. Briefly, this review provides possible screening methods to distinguish the different classes of ligands. It also deals with the structural elements and functional groups in the adenosine A1 receptor ligands that determine their intrinsic activity.
Keywords: adenosine receptor, inverse agonism, a1 receptor, intrinsic activity, partial agonism
Current Pharmaceutical Design
Title: Intrinsic Activity at Adenosine A1 Receptors: Partial and Inverse Agonism
Volume: 8 Issue: 26
Author(s): Rianne A.F. de Ligt and Ad P. Ijzerman
Affiliation:
Keywords: adenosine receptor, inverse agonism, a1 receptor, intrinsic activity, partial agonism
Abstract: Novel phenomena, such as constitutive activity and inverse agonism, have led to a ligand (re)classification along an agonists-neutral antagonist-inverse agonist continuum. This review focuses on adenosine A1 receptor ligands and their intrinsic activity (α). The intrinsic activity of a ligand depends both on the chemical characteristics of the compound itself and on the experimental conditions in which it is assayed. Consequently, due to this tissue-dependency determination of a ligands intrinsic activity is not always easily performed. Meanwhile, this feature may also be used in a profitable manner, namely to separate desired and unwanted effects of the drug. Briefly, this review provides possible screening methods to distinguish the different classes of ligands. It also deals with the structural elements and functional groups in the adenosine A1 receptor ligands that determine their intrinsic activity.
Export Options
About this article
Cite this article as:
de Ligt A.F. Rianne and Ijzerman Ad P., Intrinsic Activity at Adenosine A1 Receptors: Partial and Inverse Agonism, Current Pharmaceutical Design 2002; 8 (26) . https://dx.doi.org/10.2174/1381612023392874
DOI https://dx.doi.org/10.2174/1381612023392874 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotective Effects of Nonsteroidal Anti-inflammatory Drugs on Neurodegenerative Diseases
Current Pharmaceutical Design MCM-41-SO3H as an Advanced Nanocatalyst for the Solvent-Free Synthesis of N-aryl-2-amino-1,6-naphthyridine Derivatives
Current Nanoscience Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Editorial (Thematic Issue: Lipidic Nano-carrier Delivery of “Big” Molecules)
Current Pharmaceutical Biotechnology Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
Current Vascular Pharmacology Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Mini-Reviews in Medicinal Chemistry Regeneration of Mammalian Skeletal Muscle: Basic Mechanisms and Clinical Implications
Current Pharmaceutical Design Delivery systems for biopharmaceuticals. Part II: Liposomes, Micelles, Microemulsions and Dendrimers
Current Pharmaceutical Biotechnology Optimized Turmeric Extract Reduces β-Amyloid and Phosphorylated Tau Protein Burden in Alzheimer’s Transgenic Mice
Current Alzheimer Research Recent Advances in the Synthesis of C-linked Glycoconjugates
Current Topics in Medicinal Chemistry Mevalonate Cascade and Small Rho GTPase in Spinal Cord Injury
Current Molecular Pharmacology Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain
Current Neuropharmacology New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology